Global X Genomics & Biotechnology ETF (NASDAQ: GNOM)

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM), Trade Ideas

Biotech

Long Ideas

Sector ETFs

Trading Ideas

ETFs

General

ARKG

GNOM

MRNA

AKRG

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

3 Genomics ETFs Worth Jumping For

Health Care

This High Growth ETF May Not Be As Pricey As You Think

News

New ETFs

BMRN

ILMN

VRTX

Get In On Genomics With This New ETF

Global X Genomics & Biotechnology ETF

GNOMESTAR CRAFT INC by GNOMESTAR CRAFT INC

Gnomestar Craft Inc

Full List:&nbsp;EYE, FIVN, BLDR, HUBS, GO, SNPS, NTLA, PCTY, TTEC, REZI, SI, GRBK, CARR, DRIV, IPHI, MELI, CDNS, TA, TMO, GNOM, HERO, DNKN, GNRC, CAF, QCLN, SFTTW, DVA, CROX, MCHI, MGNI, IIPR, BEEM, LRCX, SAIL, RACE, HOLX, TER, SNE, ADI, FTCH, SMH, SOXX, LSCC, MTCH, GOOGL, XLNX, MXIM, QQQJ, HEAR, KLAC, GOOG, U, ORBC, OIIM, GDS, SE, DHR, GMAB, BEKE, CRSR, NIU, UPWK, QCOM, ALTM, PDD, NIO, XPEV, JD

ALTM

BEEM

BEKE

BLDR

CARR

CDNS

CROX

CRSR

DNKN

DRIV

FIVN

FTCH

GMAB

GNRC

GOOG

GOOGL

GRBK

HEAR

HERO

HOLX

HUBS

IIPR

IPHI

KLAC

LRCX

LSCC

MCHI

MELI

MGNI

MTCH

MXIM

NTLA

OIIM

ORBC

PCTY

Citigourp Global Markets 2% Protected Notes Linked To The Djia

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

QCOM

QQQJ

RACE

REZI

SAIL

SFTTW

SNPS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TTEC

UPWK

XLNX

XPEV

68 Stocks Trading Near 52-Week Highs Just After Open On Thursday, Nov. 5, 2020:

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.
Within the group of <a href="https://www.benzinga.com/general/biotech/20/05/15974487/3-biotech-etfs-up-10-or-more-over-the-last-month">top-performing health care ETFs</a> are genomics funds. Entering 2020, the genomics industry was already on a compelling trajectory with declining gene sequencing costs bolstering the long-term case for related investments.
The race for a coronavirus solution is merely icing on the cake for some of the funds in this category, particularly those that Moderna (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) allocations prior to that name ascending <a href="https://www.benzinga.com/general/biotech/20/05/16061068/3-etfs-for-more-moderna-bets">to story stock status</a>.
There are multiple genomics ETFs to consider. Here&#39;s a trio of standouts from the category.
Benzinga is covering every angle of how the coronavirus affects the financial world.&nbsp;For daily updates,&nbsp;<a href="https://share.hsforms.com/1UT8L-e6gSUiP288QJFLp2A1npzh">sign up for our coronavirus newsletter</a>.
<h3>ARK Genomic Revolution ETF (ARKG)</h3>
There are story stocks in the genomics space and the ARK Genomic Revolution ETF (NYSE:AKRG) is the story ETF of the group with a year-to-date gain of almost 48%, one that includes a recent string of all-time highs.
ARKG is also one of the best-performing equity-based actively managed ETFs on the market and one of the leading health care ETFs over the past several years. Active management is an advantage here as it allows ARKG managers to allocate to coronavirus vaccine plays. However, the fund was already involved with some of those names heading into this year to go along with broader genomics exposure, which remains compelling.
&ldquo;Genomic sequencing is changing the way biological information is collected, processed, and applied. ARKG is focused on the disruptive innovations that are increasing precision, restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life,&rdquo; <a href="https://ark-funds.com/arkg" target="_blank">according to ARK Investment Management</a>.
<h3>Global X Genomics &amp; Biotechnology ETF (GNOM)</h3>
Up more than 14% over the past month, the Global X Genomics &amp; Biotechnology ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnom#NASDAQ">GNOM</a>) is on its own all-time high run. GNOM, which turned a year old last month, follows the Solactive Genomics Index.
GNOM member firms are &ldquo;companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology,&rdquo; <a href="https://www.globalxetfs.com/funds/gnom/">according to Global X</a>.
Among GNOM&#39;s top 10 holdings, a group combining for about 40% of the fund&#39;s weight, coronavirus vaccine leverage is light, but that theme is accessible further down the GNOM roster.
<h3>Franklin Genomic Advancements ETF (HELX)</h3>
The Franklin Genomic Advancements ETF (CBOE: HELX) is the newest member of the genomics ETF fray having debuted in February. Like the aforementioned ARKG, HELX is actively managed and its returns are impressive as highlighted by a nearly 25% gain since inception.
HELX holds 55 stocks with a weighted average market capitalization of $21.69 billion and none of those components exceed weights of 4.70%.
The annual fee of 0.50%, or $50 on a $10,000 investment, is attractive relative to other actively managed biotech funds &ndash; both ETFs and mutual funds.

When it comes to growth stocks, investors often expect they will pay up to access that. That&#39;s the cost of investing in companies with thrilling rates of earnings growth. In theory, this is even more the case in new, technologically disruptive industries.
<h3>What Happened</h3>
Genomics fits the bill as disruptive in the health care arena and many of the investable companies in this space are classified as biotech stocks, a group that typically commands earnings premiums relative to the broader healthcare sector.
Upon closer examination, the newly minted Global X Genomics &amp; Biotechnology ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnom#NASDAQ">GNOM</a>) may not be as richly value as investors may think it is. GNOM, which debuted in April, tracks Solactive Genomics Index.
<h3>Why It&#39;s Important</h3>
In a world of unprofitable &ldquo;unicorns,&rdquo; it&#39;s increasingly important for investors to ascertain why some companies bleed cash. Some have no clear, near-term path to profitability. Others may be investing in their businesses, facilitating growth and not hoarding cash. The latter could be the case with some GNOM components.
&ldquo;One example of this is in the genomics space, where high R&amp;D costs mean many leading firms in the space often lose money until they develop and receive approval of a successful drug,&rdquo; <a href="https://www.globalxetfs.com/how-to-value-disruptive-themes/">said Global X in a recent note</a>. &ldquo;Just because they are not profitable currently, does not mean their business model is unable to capture positive earnings in the future.&rdquo;
In a fast-growing, disruptive universe like genomics, it may be more relevant for investors to focus on sales metrics rather than price-to-earnings multiples. Yes, GNOM has a negative price-to-earnings ratio, but that isn&#39;t necessarily an indictment of the fund.
&ldquo;If total sales are low, but growth is very high, it is likely in the earlier stages of adoption than if total sales are large, but growth is flattening,&rdquo; according to Global X.
<h3>What&#39;s Next</h3>
Based on price-to-sales and enterprise value/sales, GNOM is expensive relative to the S&amp;P 500. However, data indicate the fund trades at just 0.19 times price-to-sales growth and 0.17 times enterprise value/sales growth.
Those figures are not only low compared to the S&amp;P 500, but low relative to other disruptive themes, including cannabis, robotics and social media.
Related Links:
<a href="https://www.benzinga.com/trading-ideas/long-ideas/19/10/14565063/an-unsung-consumer-staples-etf">A Nifty Consumer Staples ETF</a>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/19/10/14556837/new-graniteshares-etf-weeds-out-companies-vulnerable-to-technological-disruption">This New ETF Avoids Weak Stocks</a>

Since the completion of the National Institutes of Health and Department of Energy-funded Human Genome Project in 2003, genomics has been one of the most compelling areas of the biotechnology universe.
Genomics investing is now more accessible thanks to Tuesday&#39;s debut of the Global X Genomics &amp; Biotechnology ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnom#NASDAQ">GNOM</a>).
<h3>What Happened</h3>
GNOM targets the Solactive Genomics Index and aim of the new ETF is to &ldquo;invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology,&rdquo; <a href="https://www.globalxfunds.com/funds/gnom/">according to Global X</a>.
GNOM&#39;s underlying index is home <a href="https://www.globalxfunds.com/content/files/Global-X-Genomics-and-Biotechnology-ETF.pdf">to 40 stocks</a> and the benchmark&#39;s top 10 holdings each command weights of 4 percent. The new ETF&#39;s lineup includes names familiar to biotechnology investors, such as Vertex Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>), Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) and BioMarin Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrn#NASDAQ">BMRN</a>).
<h3>Why It&#39;s Important</h3>
Wide-ranging applications for genomics bolster the case for GNOM. Doctors, researchers and scientists use genomics in endeavors such as gene editing and sequencing, computational genomics, development of genetic testing and broader biotechnology concepts. Moreover, the gene sequencing market is expected to experience exponential growth in the coming years.
&ldquo;Estimates suggest that the global DNA sequencing market was valued at $6.2 billion in 2017 and is expected to reach $25.5 billion in 2025, with a compound annual growth rate (CAGR) of 19 percent,&rdquo; <a href="https://www.globalxfunds.com/science-behind-genomics/">according to Global X research</a>.
Computational genomics, which uses statistical data to glean insights from genome sequences, is another fast-growing market that could benefit GNOM over the long term.
&ldquo;The global computational biology market is expected to value $6.8 billion in 2024, up from $2.3 billion today with a CAGR of 19.5 percent,&rdquo; said Global X.
Computational genomics is currently being used to find treatments for complex diseases, including Alzheimer&#39;s, cancer and diabetes, among others.
<h3>What&#39;s Next</h3>
GNOM enters a crowded segment of the ETF space. With the debut of the Global X fund, there are now almost 20 U.S.-listed biotechnology ETFs, including leveraged funds.
GNOM has an annual fee of 0.68 percent, or $68 on a $10,000 investment. While that is higher the fees found on basic biotechnology ETF&#39;s GNOM undercuts the 0.75 percent charged by an existing, actively managed genomics ETF <a href="https://etfdb.com/etfs/industry/biotechnology/#etfs__expenses&amp;sort_name=expense_ratio&amp;sort_order=asc&amp;page=1">and the fees</a> found on several other highly focused, passive biotech ETFs.
Related Links
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/19/04/13504965/a-perfect-etf-for-frugal-and-new-investors-alike">A Great Cheap ETF</a>
<a href="https://www.benzinga.com/general/biotech/19/04/13505218/big-moves-in-leveraged-biotech-etfs">Big Action In These Leveraged ETFs</a>

Futures Slightly Lower After Mixed Tuesday

U.S. equity futures were slightly lower in early pre-market trade after a mixed day on Wall Street Tuesday. The Dow Jones Industrial Average was able to close at a new record high but the S&amp;P 500 slipped slightly on Tuesday away from its record close.

Top News
In other news around the markets:

<ul><li> </li><li> French Non-Farm Payrolls fell 0.3 percent in February, below expectations of a drop of 0.2 percent in the month which would have been a flat reading month-over-month. </li><li> Carl Icahn reportedly increased his stake in Herbalife (NYSE: <a class="ticker" href="/stock/hlf#NYSE">HLF</a>) on March 8 but no filing has been made yet. The news came after headlines that the company was not the subject of an FTC investigation, which would be a huge blow to noted bear Bill Ackman. </li><li> Boeing (NYSE: <a class="ticker" href="/stock/ba#NYSE">BA</a>) was given the go-ahead by the FAA to test its new battery casing as it looks to get the grounded 787 Dreamliner back in the air. </li><li> S&amp;P 500 futures fell 1.1 points to 1,545.70. </li><li> The EUR/USD was lower at 1.3022. </li><li> Spanish 10-year government bond yields were flat at 4.72 percent. </li><li> Italian 10-year government bond yields were higher at 4.63 percent from 4.6 percent. </li><li> Gold fell 0.12 percent to $1,589.90 per ounce.</li></ul>

Asian Markets
Asian shares were lower overnight on little news on fear of a new slowdown in China weighing on the global economy. The japanese Nikkei Index fell 0.61 percent and the Shanghai Composite Index fell 0.99 percent and the Hang Seng Index declined 1.46 percent. Also, the Korean Kospi rose 0.32 percent on reports of a new fiscal stimulus and Australian shares fell 0.5 percent.

European Markets
European shares were lower in early trade ahead of the industrial production release for the eurozone on some weak earnings from companies such as Inditex and rumors of a secondary offering to fill a capital shortfall at Commerzbank (OTC: <a class="ticker" href="/stock/crzby#OTC">CRZBY</a>). The Spanish Ibex Index fell 0.31 percent and the Italian FTSE MIB Index fell 0.43 percent as leaders could not form a coalition in the Senate. Meanwhile, the German DAX fell 0.08 percent and the French CAC fell 0.31 percent while U.K. shares declined 0.63 percent.

Commodities
Commodities were mixed overnight as energy futures led after Goldman Sachs (NYSE: <a class="ticker" href="/stock/gs#NYSE">GS</a>) analysts released a note saying that the commodity sell off was overdone. WTI Crude futures rose 0.43 percent to $92.94 per barrel and Brent Crude futures rose 0.16 percent to $109.87 per barrel. Copper futures fell 0.11 percent to $355.05 on global growth fears. Gold was lower and silver futures declined 0.43 percent to $29.05 per ounce.

Currencies
Currency markets were in a strong reversal mode as the pound gained and the yen gained as well on fears that further easing in both economies is not as near as originally thought. The EUR/USD was lower at 1.3022 and the dollar fell against the yen to 95.78. Overall, the Dollar Index fell 0.04 percent on weakness against the pound, the yen, the Swiss franc and the Swedish krone. The GBP/USD rose 0.4 percent, reversing Tuesday's losses, to 1.4962 and the EUR/GBP fell 0.48 percent to 0.8703 making the pound the biggest mover overnight alongside the yen.

Pre-Market Movers
Stocks moving in the pre-market included:

<ul><li> </li><li> Boeing (NYSE: <a class="ticker" href="/stock/ba#NYSE">BA</a>) shares rose 0.76 percent pre-market after the company got approval to test the 787 Dreamliner again by the FAA. </li><li> J.C. Penny (NYSE: <a class="ticker" href="/stock/jcp#NYSE">JCP</a>) shares fell 0.89 percent pre-market after rumors that CEO Ron Johnson was set to leave the company were quashed Tuesday. </li><li> Spectrum Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/sppi#NASDAQ">SPPI</a>) shares fell 40.47 percent pre-market on lower than expected guidance. </li><li> Yandex (NASDAQ: <a class="ticker" href="/stock/yndx#NASDAQ">YNDX</a>) shares rose 0.52 percent after falling 7.99 percent Tuesday on a secondary offering.</li></ul>

Earnings
Notable companies expected to report earnings Wednesday include:

<ul><li> </li><li> Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) is expected to report a fourth quarter loss of $0.53 per share vs. a loss of $0.67 per share a year ago. </li><li> Express Inc. (NYSE: <a class="ticker" href="/stock/expr#NYSE">EXPR</a>) is expected to report fourth quarter EPS of $0.74 vs. $0.70 a year ago. </li><li> Guess? (NYSE: <a class="ticker" href="/stock/ges#NYSE">GES</a>) is expected to report fourth quarter EPS of $0.87 vs. $1.05 a year ago. </li><li> Hot Topic (NASDAQ: <a class="ticker" href="/stock/hott#NASDAQ">HOTT</a>) is expected to report fourth quarter EPS of $0.27 vs. $0.21 a year ago. </li><li> The Men's Warehouse (NYSE: <a class="ticker" href="/stock/mw#NYSE">MW</a>) is expected to report a fourth quarter loss of $0.05 per share vs. a loss of $0.05 per share a year ago.</li></ul>

Economics
On the economics calendar Wednesday, MBA Purchase Applications, Retail Sales, Import and Export Prices, and Business Inventories are due out. Also, the Treasury is set to auction 10-year notes. Overnight, the Australian employment report, Swiss National Bank rate decision, and ECB Monthly Report could move markets.

Good luck and good trading.

Analyst Color

Earnings

Bonds

Guidance

Dividends

Rumors

Financing

Futures

Commodities

Previews

Forex

Retail Sales

Events

Global

Econ #s

Economics

Pre-Market Outlook

Markets

Analyst Ratings

Movers

BROAD

BZSUM

CRZBY

EARLY

EXPR

HOTT

SPPI

YNDX

Benzinga Market Primer: Wednesday, March 13

BGI-Shenzhen ("BGI") and Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") announced today that they have obtained approval from the Ministry of Commerce of the People's Republic of China regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
BGI and Complete are awaiting approval of the State Administration of Foreign Exchange of the People's Republic of China regarding the proposed acquisition.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free, at (888) 750-5834.
FORWARD-LOOKING STATEMENTS
Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both BGI's and Complete's actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited
 <a href="http://www.benzinga.com/pressreleases/13/02/n3365312/bgi-shenzhen-and-complete-genomics-inc-receive-approval-from-the-minist">See full press release</a>

Asset Sales

Management

BGI-Shenzhen Receives Approval from Ministry of Commerce of PRC for Proposed Acquisition Of Complete Genomics

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Friday February 22, 2013:

Ark Restaurants Rejects Landry's $22/Share Bid

The Rejection: Ark Restaurants (NASDAQ: <a class="ticker" href="/stock/arkr#NASDAQ">ARKR</a>) said Friday that its Board of Directors has decided that the unsolicited proposal from Landry's to acquire Ark Restaurants for $22 per share is inadequate and not in the best interests of Ark Restaurants shareholders. 

Michael Weinstein, Chairman and CEO of Ark Restaurants, commented: “The Board believes that the proposal by Landry's significantly undervalues the Company and its future prospects. In the Board's judgment, Ark's shareholders will be better served by our experienced management operating and growing our business.”

Ark Restaurants closed at $21.42 Friday, a gain of 1.5% on 3 times average volume.

Report Gardner Denver Board to Meet Monday to Consider KKR's $75/Share Offer

The Rumor: The Board of Direcrtors of Gardner Denver (NYSE: <a class="ticker" href="/stock/gdi#NYSE">GDI</a>) will meet on Monday to consider KKR's (NYSE: <a class="ticker" href="/stock/kkr#NYSE">KKR</a>) $75 per share bid, according to Reuters. On Thursday, Bloomberg had reported the $3.7 billion offer for KKR.

KKR has declined comment, while Gardner Denver has not responded. 

Gardner Denver closed at $70.84 Friday, a gain of 5% on 3.5 times average volume.

BGI-Shenzhen Extends Tender Offer Again for Complete Genomics

The Tender Offer: BGI-Shenzhen said Friday that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>), for $3.15 per share, to 12:00 midnight (New York City time) on Friday, March 1, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, February 22, 2013. 

Complete Genomics closed at $3.11 Friday, a loss of $0.01 on lower than average volume.

Short Ideas

After-Hours Center

ARKR

Benzinga's M&A Chatter for Friday February 22, 2013

BGI-Shenzhen ("BGI") announced today that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (New York City time) on Friday, March 1, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, February 22, 2013.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on February 22, 2013, approximately 30,807,293 shares, or approximately 87%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer, or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free,
 <a href="http://www.benzinga.com/pressreleases/13/02/n3359424/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

Contracts

BGI-Shenzhen Extends Tender Offer for Complete Genomics to Friday, February 22, 2013

BGI-Shenzhen ("BGI") announced Wednesday that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (New York City time) on Friday, February 22, 2013. BGI has extended the expiration date of the Offer to provide additional time for approval by the Ministry of Commerce of the People's Republic of China (the "PRC") and subsequent registration with the State Administration of Foreign Exchange of the PRC of the transaction, particularly in view of the upcoming Chinese New Year holiday period, which begins on February 9, 2013 and ends on February 15, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Wednesday, February 6, 2013.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on February 6, 2013, approximately 30,967,711 shares, or approximately 87%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including
 <a href="http://www.benzinga.com/pressreleases/13/02/n3311786/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Extends Tender Offer For Complete Genomics to Friday, February 22, 2013

BGI-Shenzhen ("BGI") announced today that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (EST) on Friday, February 1, 2013. The Offer was previously scheduled to expire at 12:00 midnight (EST) on Friday, January 25, 2013.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on January 25, 2013, approximately 30,949,757 shares, or approximately 87%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer, or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free at (888) 750-5834.
FORWARD-LOOKING STATEMENTS
Certain statements
 <a href="http://www.benzinga.com/pressreleases/13/01/n3276239/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Extends Tender Offer for Complete Genomics

BGI-Shenzhen ("BGI") and Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") announced Friday that they have obtained clearance from the National Development and Reform Commission of the People's Republic of China regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free, at (888) 750-5834.
FORWARD-LOOKING STATEMENTS
Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both the BGI's and Complete's actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited to, statements regarding the combined companies' plans following, and the expected completion of, the proposed acquisition. These forward-looking statements involve
 <a href="http://www.benzinga.com/pressreleases/13/01/n3236940/bgi-shenzhen-and-complete-genomics-inc-receive-clearance-from-the-natio">See full press release</a>

BGI-Shenzhen and Complete Genomics Receive Clearance from China Regulatory Agency for Merger

BGI-Shenzhen ("BGI") announced Friday that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (New York City time) on Friday, January 18, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, January 11, 2013.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on January 11, 2013, approximately 29,336,700 shares, or approximately 83%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete may call the Information Agent,
 <a href="http://www.benzinga.com/pressreleases/13/01/n3236937/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Announces an Additional Extension of Tender Offer for Complete Genomics

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Tuesday January 8, 2013:

Vivus CEO Reportedly Says Acquisition is 'Inevitable'

CEO Comments: Vivus (NASDAQ: <a class="ticker" href="/stock/vvus#NASDAQ">VVUS</a>) CEO Leland Wilson, talking to Deal Reporter at the J.P. Morgan Healthcare Conference in San Francisco, said partnership talks have been ongoing and a deal could be reached by year end. Wilson reportedly said a takeover is "inevitable", and said it's a matter "of when and at what price."

Vivus shares traded as high as $15.12 on the report, but closed down 3% at $14.43 on twice average volume.

Hearing Renewed Chatter of Icahn Stake in Research in Motion

The Rumor: Shares of Research in Motion (NASDAQ: <a class="ticker" href="/stock/rimm#NASDAQ">RIMM</a>) surged higher in early trading on Tuesday, on unconfirmed chatter that investor Carl Icahn was going to take a significant stake in the Blackberry maker. On November 13, 2012, another unconfirmed report had Icahn leading a group of investors to buy RIMM for $13 per share.

A spokesperson for Research in Motion declined comment on the rumor.

Research in Motion closed at $11.91 Tuesday, a loss of $0.04 on average volume.

Hearing Unconfirmed Chatter Google Could Bid for Virnetx Holding

The Rumor: Hearing unconfirmed market chatter that Google (NASDAQ: <a class="ticker" href="/stock/goog#NASDAQ">GOOG</a>) could bid $50 per share to acquire Virnetx Holding (NYSE: <a class="ticker" href="/stock/vhc#NYSE">VHC</a>) in order to obstruct Apple's (NASDASQ: AAPL) court case and/or settlement talks.

A spokesperson for Google declined comment on the rumor. A Virnetx spokesperson was not available for comment.

Virnetx Holding closed at $33.49 Tuesday, a gain of 1.5% for the day on average volume.

Hearing Illumina Withdraws Bid for Complete Genomics

The Offer: Illumina (NASDAQ: <a class="ticker" href="/stock/ilmn#NASDAQ">ILMN</a>) reportedly has withdrawn its bid to acquire Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>), according to sources. Illumina had bid $3.30 to acquire Complete Genomics. That offer was rejected by GNOM's Board of Directors in November 2012.

On Monday, BGI-Shenzhen subsidiary Beta Acquisition Corporation, extended its all-cash tender offer to acquire Complete Genomics for $3.15 per share, till January 11, 2013.

Complete Genomics closed at $3.15 Tuesday, a loss of 1.5% for the day on 8.5 times average volume.

Detwiler Note Says True Religion Deal Less Likely Now

The Analyst Note: A note from Detwiler Tuesday said not to expect an acquisition of True Religion (NASDAQ: <a class="ticker" href="/stock/trlg#NASDAQ">TRLG</a>) to be announced in the short-term. It cited poor holiday sales as a reason to doubt a deal could be done at all.

True Religion began a strategic review process on October 10, 2012. Deal Reporter reported on December 3 that private equity firms were losing interest.

True Religion Apparel closed at $24.54 Tuesday, a loss of 3.5% on higher than average volume.

Dish Offers $3.30/Share for Clearwire

The Offer: DISH Network (NASDAQ: <a class="ticker" href="/stock/dish#NASDAQ">DISH</a>) confirmed Tuesday that it has formally approached Clearwire Corporation (NASDAQ: <a class="ticker" href="/stock/clwr#NASDAQ">CLWR</a>) with respect to a potential strategic transaction on terms as generally outlined in the Clearwire release, including an offer to purchase all of the Clearwire common shares at $3.30.

Clearwire confirmed that it has received the unsolicited, non-binding proposal from DISH Network.

Sprint (NYSE: <a class="ticker" href="/stock/s#NYSE">S</a>) announced on December 17, 2012 that it had entered into a definitive agreement to acquire the approximately 50 percent stake in Clearwire it does not currently own for $2.97 per share.

Clearwire closed at $2.92 Tuesday, but traded at $3.15 after the Dish offer was announced.

CLWR

DISH

RIMM

TRLG

VVUS

Benzinga's M&A Chatter for Tuesday January 8, 2013

Illumina Withdraws Offer to Buy Complete Genomics

BGI-Shenzhen ("BGI") announced today that it, through its wholly owned subsidiary Beta Acquisition Corporation,&nbsp; has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (New York City time) on Friday, January 11, 2013. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Monday, January 7, 2013.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged.&nbsp; The Depositary for the Offer has indicated that, as of the close of business on January 4, 2013, approximately 17,862,560 shares, or approximately 50%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information
 <a href="http://www.benzinga.com/pressreleases/13/01/n3218635/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Extends All-Cash Tender Offer for Complete Genomics to January 11, 2013

BGI-Shenzhen announced Friday that it, through its wholly owned subsidiary Beta Acquisition Corporation,&nbsp; has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 am ET on Monday, January 7, 2013. The Offer was previously scheduled to expire at 12:00 am ET on Monday, December 31, 2012.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged.&nbsp; The Depositary for the Offer has indicated that, as of the close of business on December 28, 2012, approximately 17,822,265 shares, or approximately 50%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free, at (888) 750-5834.
FORWARD-LOOKING STATEMENTS
Certain statements
 <a href="http://www.benzinga.com/pressreleases/12/12/n3204610/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Extends All-Cash Tender Offer for Complete Genomics

BGI-Shenzhen and Complete Genomics. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) announced Friday that they have obtained clearance from the Committee on Foreign Investment in the United States ("CFIUS") regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company, and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free, at (888) 750-5834.
FORWARD-LOOKING STATEMENTS
Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both the BGI's and Complete's actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited to, statements regarding the combined companies' plans following, and the expected completion of, the proposed acquisition. These forward-looking statements involve certain risks
 <a href="http://www.benzinga.com/pressreleases/12/12/n3204611/bgi-shenzhen-and-complete-genomics-inc-receive-cfius-clearance-for-bgi-">See full press release</a>

BGI-Shenzhen Receives CFIUS Clearance for Proposed Acquisition of Complete Genomics

BGI-Shenzhen ("BGI") announced today that it, through its wholly owned subsidiary Beta Acquisition Corporation,&nbsp;has extended its all cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Complete Genomics,&nbsp;Inc. (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) ("Complete") to 12:00 midnight (New York City time) on Monday, December 31, 2012. The Offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, December 14, 2012.&nbsp; 
Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged.&nbsp; The Depositary for the Offer has indicated that, as of the close of business on December 13, 2012, approximately 14,364,134 shares, or approximately 40%, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny &amp; Myers LLP. Complete's financial adviser is Jefferies &amp; Company and its legal counsel is Latham &amp; Watkins LLP.
Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&amp;A Incorporated, toll-free,
 <a href="http://www.benzinga.com/pressreleases/12/12/n3173042/bgi-shenzhen-extends-tender-offer-for-complete-genomics-inc">See full press release</a>

BGI-Shenzhen Announces Extension of Tender Offer For Complete Genomics

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Wednesday November 21, 2012:

Reckitt Benckiser to Acquire Schiff Nutrition for $42/Share in Cash

The Deal: Reckitt Benckiser Group (OTC: <a class="ticker" href="/stock/rbgpf#OTC">RBGPF</a>) announced Wednesday it had signed a definitive merger agreement with Schiff Nutrition International (NYSE: <a class="ticker" href="/stock/shf#NYSE">SHF</a>) to acquire Schiff for $42.00 per share in cash or $1.4 billion. Reckitt Benckiser will finance the transaction with cash and existing credit facilities. The transaction is expected to be immediately accretive to earnings on an adjusted basis.

Reckitt Benckiser expects the tender offer to close before the end of calendar year 2012.

Schiff Nutrition closed at $41.90 Wednesday, a gain of 0.10% on lower than average volume.

Complete Genomics Rejects Illumina Takeover Offer

The Rejection: The Board of Directors of Complete Genomics (NASDAQ: <a class="ticker" href="/stock/gnom#NASDAQ">GNOM</a>) rejected Illumina's (NASDAQ: <a class="ticker" href="/stock/ilmn#NASDAQ">ILMN</a>) proposal to acquire Complete Genomics for $3.30 in cash for each outstanding share.

On September 17, 2012 Complete Genomics and BGI-Shenzhen announced that they had entered into a definitive merger agreement, whereby a wholly-owned U.S. subsidiary of BGI would launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash.

A letter from Illumina CEO Jay Flatley to the Complete Genomics Board of Directors indicated Illumina's offer was superior to BGI's saying "BGI's proposal is subject to a number of conditions including, among other things, (1) receipt of financing, (2) approval of the Committee on Foreign Investment in the United States (“CFIUS”) under the Exon-Florio Act, and (3) expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act."

Complete Genomics closed at $3.16 Wednesday, a gain of a 2.27% on twice average volume.

Hearing Unconfirmed Chatter of Bain/TPG Bid for Seagate Technology

The Rumor: Bain Capital and TPG Capital are rumored to be making a $36 per share bid for Seagate Technology (NASDAQ: <a class="ticker" href="/stock/stx#NASDAQ">STX</a>), according to unconfirmed chatter circulating. 

A spokesperson for Bain Capital told Benzinga there was no truth to the rumor. Spokespersons for Seagate and TPG declined comment.

Seagate Technology closed at $26.75 Wednesday, up $0.13 on average volume.

Hearing Unconfirmed Chatter of IBM Bid for Fusion-IO

The Rumor: IBM (NYSE: <a class="ticker" href="/stock/ibm#NYSE">IBM</a>) is rumored to be making a bid of $3.4 billion to acquire Fusion-IO (NYSE: <a class="ticker" href="/stock/fio#NYSE">FIO</a>), according to unconfirmed chatter circulating. The company is a frequent takeover name, with EMC (NYSE: <a class="ticker" href="/stock/emc#NYSE">EMC</a>), Apple (NASDAQ: <a class="ticker" href="/stock/aapl#NASDAQ">AAPL</a>) and Intel (NASDAQ: <a class="ticker" href="/stock/intc#NASDAQ">INTC</a>) also being mentioned as potential suitors in the past.

Spokespersons for Fusion-IO and IBM were not available for comment.

Fusion-IO closed at $24.11 Wednesday, a gain of about 5% on almost twice average volume.

Report Alibaba-SINA Deal is Off

The Rumor: On November 19, 2012, China Business News reported Alibaba Group will invest $3 billion in SINA's (NASDAQ: <a class="ticker" href="/stock/sina#NASDAQ">SINA</a>) Weibo microblogging platform.

A report Wednesday from <a href="http://news.imeigu.com/a/1353504496594.html">imeigu.com</a>, citing Netease, appeared to indicate the deal may be off, due to disagreement on price.

Spokespersons for the two companies were not available for comment.

SINA closed at $47.30 Wednesday, a gain of $0.30 on average volume.

Pacific Drilling May be Takeover Target

The Rumor: Pacific Drilling (NYSE: <a class="ticker" href="/stock/pacd#NYSE">PACD</a>) is a takeover target according to <a href="http://ftalphaville.ft.com/2012/11/21/1274583/is-someone-circling-pacific-drilling/?">FT Alphaville</a>.

Seadrill (NYSE: <a class="ticker" href="/stock/sdrl#NYSE">SDRL</a>) and Ensco (NYSE: <a class="ticker" href="/stock/esv#NYSE">ESV</a>) are among the interested suitors, according to the report, with a bid of $13.80 rumored from one buyer.

A spokesperson for Pacific Drilling was not available for comment.

Pacific Drilling closed at $9.85 Wednesday, a loss of $0.05 on 3 times average volume.

AAPL

INTC

PACD

RBGPF

SDRL

SINA

Benzinga's M&A Chatter for Wednesday November 21, 2012

November 20, 2012 

Board of Directors 

Complete Genomics, Inc. 

2071 Stierlin Court 

Mountain View, CA 94043 

Gentlemen: 

I was disappointed to learn that the Board of Directors of Complete Genomics, Inc. summarily rejected Illumina, Inc.'s proposal to enter into a business combination transaction in which Illumina would acquire Complete Genomics, Inc. at a price of $3.30 in cash for each outstanding share. We believe, and think that Complete Genomics shareholders would agree, that our Proposal is superior to the proposed acquisition by BGI Shenzen for $3.15 per share. The price per share offered under our Proposal represents a premium of 5% to the BGI proposal. Our Proposal is not subject to any additional due diligence, and unlike the proposed BGI transaction is not contingent on financing or CFIUS approval. With respect to antitrust approvals, we are confident that our proposed transaction would be approved, and raises fewer regulatory concerns than the proposed BGI transaction. In light of that, we cannot comprehend how your Board of Directors could rationally come to the conclusion that our Proposal is not superior to BGI's proposal, or how rejection of our Proposal without discussion could satisfy your Board's obligation to the shareholders of Complete Genomics. 

Your agreement with BGI allows Complete Genomics to engage in transaction discussions with others if your Board of Directors determines that a third party proposal is, or could reasonably be expected to result in, a “Superior Proposal”; i.e., a proposal that is (1) more favorable to Complete Genomics shareholders from a financial point of view than the BGI proposal, and (2) reasonably capable of being consummated on the terms proposed. We believe that our proposal meets both criteria. In addition to providing demonstrably superior value, we believe our Proposal can be consummated on the terms proposed and, in fact, offers your shareholders greater closing certainty than BGI's proposal for the reasons discussed below. 

BGI's proposal is subject to a number of conditions including, among other things, (1) receipt of financing, (2) approval of the Committee on Foreign Investment in the United States (“CFIUS”) under the Exon-Florio Act, and (3) expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. More than two months after having announced your proposed transaction with BGI, these conditions have not yet been satisfied. In fact, you recently received a “second request” from the FTC, indicating sufficient antitrust concerns to merit an investigation under the HSR. Furthermore, while you have made no disclosure of the status of your CFIUS filing, we believe that there are serious concerns raised by your proposed transaction with BGI that call into question whether that transaction can be completed. In contrast, our Proposal is not subject to any conditions relating to financing or CFIUS approval. 

--------------------------------------------------------------------------------

National security, industrial policy, personal identifier information protection and other concerns raised in connection with an acquisition of Complete Genomics by a foreign state owned entity create meaningful uncertainty around a BGI acquisition, and represent a material risk for your shareholders. As you may be aware CFIUS reviews of transactions involving state owned entities have been problematic, and several transactions have been abandoned rather than be subjected to a Presidential order to unwind the transaction. Recently the President issued an order to unwind such a transaction in an industry far less sensitive than ours. 

While expiration of the HSR waiting period is necessary in order to consummate our proposed transaction, we believe that our Proposal can be consummated under applicable antitrust laws, and that our combination raises fewer regulatory concerns than the BGI proposal. In light of that, your public statements characterizing Illumina's views on the antitrust aspects of the combination of our two companies - as well as comments attributed to our CEO and antitrust counsel - are inaccurate. Furthermore, your suggestion that BGI is better positioned to proliferate the technology in the marketplace, and therefore more pro-competitive, reflects a lack of understanding of Illumina's intentions and the competitive market dynamics. 

As you know, the markets in which we operate are rapidly evolving and highly competitive, in significant part because of game-changing innovations by Illumina and Complete Genomics. The combination of our companies will accelerate the pace of such innovations and result in higher quality, more innovative products available at lower costs to consumers. This combination will also further stimulate global competition in sequencing services as well as in the emerging business of genome analysis and interpretation. We believe that more significant issues for consumers and the industry are raised by the combination of Complete Genomics with a state owned entity such as BGI that is primarily focused on sequencing services than by a primarily equipment-consumables company like Illumina. 

Our Proposal has been approved by our Board of Directors and we are prepared to enter into an agreement on substantially the same terms as the agreement you entered into with BGI including the bridge financing. In this regard, we are providing you with a form of merger agreement and financing agreement that we are prepared to enter into subject to your compliance with your agreement with BGI. We have engaged Goldman, Sachs &amp; Co. and Skadden, Arps, Slate, Meagher &amp; Flom LLP as our financial and legal advisors, and are ready to meet with you at any time to discuss this Proposal in accordance with your agreement with BGI. 

Again, I believe the combination of our two companies is a tremendous opportunity for our respective shareholders, customers, and employees. I sincerely hope that your Board and management will consider the best interests of these constituencies and seek to complete this transaction promptly. 

Very truly yours, 

/s/ Jay T. Flatley 

Jay T. Flatley 

President and Chief Executive Officer

Illumina Sends Letter to Complete Genomics Board, Expecting No Antitrust Issues with Bid

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Some of the top gene-editing stocks have had immense surge potential.



Look at&nbsp;CRISPR Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>), for example.



After a positive outcome from a&nbsp;<a href="https://investorplace.com/2023/10/crsp-stock-halt-crispr-trading-halted-ahead-of-fda-decision/">U.S. FDA advisory panel</a>, and eventual&nbsp;<a href="https://www.investors.com/news/technology/crsp-stock-what-fda-approval-means-for-future-of-medicine/#:~:text=On%20Dec.,and%20beta%20thalassemia%20blood%20disorders.">U.S. FDA approval</a>&nbsp;of CRSP&rsquo;s sickle cell treatment, the stock exploded from a low of about $40 to a high of $63 a share. Then, just days ago, it also received US FDA approval for its&nbsp;gene-edited therapy for&nbsp;<a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration">transfusion-dependent beta-thalassemia (TDT)</a>&nbsp;in patients 12 years and up.&nbsp;



Even more exciting, the treatments reportedly&nbsp;<a href="https://www.fool.com/investing/2024/01/30/is-crispr-therapeutics-a-buy-in-new-bull-market/">fix the genes responsible for the diseases</a>. Then, following a one-time treatment, patients can&nbsp;<a href="https://finance.yahoo.com/news/cathie-wood-goes-bargain-hunting-101000757.html">reportedly live their lives, symptom-free</a>.&nbsp;



Even better, analysts believe the treatment could have&nbsp;<a href="https://www.fool.com/investing/2024/01/30/is-crispr-therapeutics-a-buy-in-new-bull-market/">blockbuster potential</a>.&nbsp;And while CRSP has certainly been an exciting stock to watch, there are other gene-editing stocks you may want to consider today, including:



<h2>Intellia Therapeutics (NTLA)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>


Intellia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>) may also have unprecedented surge potential long term.



At the moment, it&rsquo;s in&nbsp;<a href="https://finance.yahoo.com/news/2-gene-editing-stocks-might-134500750.html">clinical gene-editing trials for inherited diseases</a>, such as Transthyretin (ATTR) amyloidosis. This is caused by a protein called transthyretin, which can change shape and form into fibrous clumps. Those clumps can then be deposited into various organs and peripheral nerves, which can cause them to function abnormally,&nbsp;<a href="https://www.pfizer.com/news/articles/understanding_this_rare_disease_called_attr_amyloidosis#:~:text=ATTR%20amyloidosis%20is%20caused%20by,cause%20them%20to%20function%20abnormally.">as noted by Pfizer</a>.



NTLA is entering Phase 3 trials with that program.



It&rsquo;s also working on treatment for&nbsp;hereditary angioedema (<a href="https://investorplace.com/stock-quotes/hae-stock-quote/">HAE</a>), a &ldquo;rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract or airway,&rdquo;&nbsp;<a href="https://rarediseases.org/rare-diseases/hereditary-angioedema/">as noted by the National Organization for Rare Disorders</a>. With HAE, the company is&nbsp;<a href="https://seekingalpha.com/article/4651759-intellia-soon-to-be-enrollment-completion-brings-about-catalysts-in-2024">wrapping up enrollment for its Phase 2 study</a>.



With HAE, NTLA may be able to initiate a Phase 3 study by the third quarter.



<h2>Verve Therapeutics (VERV)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div>


Verve Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/verv-stock-quote/">VERV</a>) has just one treatment in clinical trials at the moment.&nbsp;



Its VERVE-101 candidate, a single-course&nbsp;in vivo&nbsp;liver base editing medicine, is &ldquo;currently being evaluated in a Phase 1b heart-1 clinical trial in patients with high-risk heterozygous familial hypercholesterolemia (HeFH), established atherosclerotic cardiovascular disease (ASCVD), and uncontrolled LDL-C levels on oral standard-of-care therapy,&rdquo;&nbsp;<a href="https://www.vervetx.com/our-programs/verve-101-102">as noted by the company</a>.



So far, a&nbsp;<a href="https://www.vervetx.com/our-programs/verve-101-102">clinical trial has shown that VERVE-101</a>&nbsp;led to reductions of disease-causing LDL-C in people living with HeFH.&nbsp;



Even better, further success could expose the company to the&nbsp;<a href="https://www.vervetx.com/our-programs/our-pipeline">31 million people around the world</a>&nbsp;dealing with familial hypercholesterolemia. From there, the company hopes to expand its scope to treat a good chunk of the global population at risk for developing atherosclerotic cardiovascular disease (ASCVD).&nbsp;



Helping,&nbsp;Eli Lilly&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) bought some of the&nbsp;<a href="https://bioprocessintl.com/bioprocess-insider/deal-making/eli-lilly-bags-beams-licensing-rights-in-verve-agreement-for-250m/">commercialization rights to VERVE-101</a>&nbsp;in October. Even more impressive,&nbsp;Krishna Yeshwant, a director at Verve Therapeutics, bought <a href="https://seekingalpha.com/news/4043743-verve-director-acquires-18m-in-company-stock">$18 million worth of VERV stock in December</a>.



<h2>Global X Genomics &amp; Biotechnology ETF (GNOM)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/gene_editing_a_1600-300x169.jpg" alt="Gene editing stocks: a concept image of a hand holding a pair of tweezers that is pulling a section off of a dna strand"><div>Source: vxhal/ShutterStock.com</div></div>


Or, if you want to diversify with most gene-editing stocks at a low cost, there&rsquo;s the&nbsp;Global X Genomics &amp; Biotechnology ETF&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gnom-stock-quote/">GNOM</a>). Since October, the ETF rallied from a low of $8.63 to a recent high of $11.87. While that may not be impressive at the moment, give it time. Further gene-editing trial success could eventually send the GNOM ETF back to $28 again.



<a href="https://www.globalxetfs.com/funds/gnom/">With an expense ratio of 0.50%,</a>&nbsp;the ETF invests in companies that could benefit from&nbsp;gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology, as noted by GlobalXETFs.com. Some of its current top holdings include CRISPR Therapeutics,&nbsp;Moderna Inc.(NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/">MRNA</a>),&nbsp;Illumina&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ilmn-stock-quote/">ILMN</a>) and&nbsp;10X Genomics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>) to name a few.



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/01/3-once-in-a-lifetime-gene-editing-stocks-with-unprecedented-surge-potential/">3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Dealmaking Outlook: Unsettled, With Bright Spots

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease">new gene-editing treatment</a> for sickle cell disease and <a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration">transfusion-dependent beta-thalassemia</a>, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions. It&rsquo;s why shares of&nbsp;CRISPR Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>) exploded from about $40 to a recent high of $70. It&rsquo;s also why it and other gene editing stocks could push aggressively higher.



While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.



<h2>Intellia Therapeutics (NTLA)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>


Intellia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>) just announced that&nbsp;interim results from the Phase 1 of its Phase 1/2 study of NTLA-2002 were published&nbsp;in the&nbsp;New England Journal of Medicine. NTLA-2002 is an investigational&nbsp;in vivo&nbsp;CRISPR-based gene editing therapy in development for hereditary angioedema.



The study found that <a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-publication-positive-interim#:~:text=The%20reported%20data%20showed%20that,through%20the%20latest%20follow%2Dup.">9 out of 10 patients remained completely attack-free</a> following the 16-week primary observation period through the latest follow-up. This could be substantial news for the&nbsp;<a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-publication-positive-interim#:~:text=About%20Hereditary%20Angioedema&amp;text=It%20is%20estimated%20that%20one,used%20to%20prevent%20swelling%20attacks.">one in 50,000 people</a>&nbsp;that are affected by the disease for which there is no current cure.



<h2>Verve Therapeutics (VERV)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/research-lab-1600-300x169.jpg" alt="Scientist using a microscope"><div>Source: Maksim Shmeljov / Shutterstock.com</div></div>


Verve Therapeutics&rsquo;&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/verv-stock-quote/">VERV</a>) recently released the results the clinical trials of its drug VERVE-101.&nbsp;The trials found the single-course&nbsp;in vivo&nbsp;liver base editing medicine led to reductions of disease-causing LDL-C in people living with heterozygous familial hypercholesterolemia.



The company is also nearing clinical trials for VERVE-102 for the treatment of&nbsp;heterozygous familial hypercholesterolemia. This drug aims to treat patients before they reach the need for VERVE-101. Approximately <a href="https://www.vervetx.com/our-programs/our-pipeline#:~:text=familial%20hypercholesterolemia%20(HeFH)-,Heterozygous%20familial%20hypercholesterolemia%20(HeFH),suffer%20from%20this%20genetic%20disease.">3 million people</a> in the U.S. and Europe suffer from this genetic disease.



<h2>Global X Genomics &amp; Biotechnology ETF (GNOM)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div>


There&rsquo;s also the&nbsp;Global X Genomics &amp; Biotechnology ETF&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gnom-stock-quote/">GNOM</a>).&nbsp;<a href="https://www.globalxetfs.com/funds/gnom/">With an expense ratio of 0.5%</a>,&nbsp;the ETF invests in companies that could benefit from&nbsp;gene editing, genomic sequencing, genetic therapy, computational genomics and biotechnology.



Since late October, the ETF ran from about $8.75 to a high of $11.75. While it did back off some, I&rsquo;d like to see the GNOM ETF push to higher highs. Especially with massive gene-editing progress being made. Some of its current top holdings include CRISPR,&nbsp;Moderna (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/">MRNA</a>),&nbsp;Illumina&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ilmn-stock-quote/">ILMN</a>) and&nbsp;10X Genomics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>).



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines</a>.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/3-gene-editing-stocks-with-unprecedented-surge-potential/">3 Gene Editing Stocks With Unprecedented Surge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Gene Editing Stocks With Unprecedented Surge Potential

Sector Insights: What Could Go Right In 2024?

Are Healthcare Stocks A Risky Prescription In A U.S. Election Year?

Why Biotech Stocks May Be Ready For A Recovery

2024 Outlook: A New 'Super Boom'? Or Chop And Churn?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.



Look at gene editing stocks, like CRISPR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>), for example.&nbsp;



Several weeks ago, the&nbsp;U.S. Federal Drug Administration approved a&nbsp;<a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease">new gene-editing treatment</a>&nbsp;for sickle cell disease and&nbsp;<a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration">transfusion-dependent beta-thalassemia,</a> a genetic disorder that prevents the production of hemoglobin in the blood.&nbsp;



Since then, CRSP has run from about $40 to a high of $90. Now back to $72.94, it&rsquo;s oversold and could easily rally back to $90 soon.&nbsp;In fact, with a pipeline full of other potential treatments for immune-oncology, autoimmune diseases, cardiovascular disease and Type 1 diabetes, the CRSP stock could race higher. Plus, with gene editing gaining major traction, the market could be worth about $29.9 billion by the time 2032 rolls around,&nbsp;<a href="https://www.biospace.com/article/releases/gene-editing-market-size-expected-to-reach-usd-29-93-bn-by-2032/">as noted by Precedence Research.</a>



Even better, there are plenty of other gene-editing stocks with similar potential. Here are three ideas you may want to jump on today.



<h2>Intellia Therapeutics (NTLA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>The last time I mentioned&nbsp;Intellia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>), it traded at around $27 a share on Feb. 13. After hitting a high of $34.87, it&rsquo;s now back to $27.78, where it just caught support. From here, I&rsquo;d like to see it initially retest prior resistance above $34.



As I noted at the time, NTLA &ldquo;announced that&nbsp;interim results from Phase 1 of its Phase 1/2 study of NTLA-2002 were published&nbsp;in the&nbsp;New England Journal of Medicine.&rdquo; It found that&nbsp;&ldquo;9 out of 10 patients remained <a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-publication-positive-interim#:~:text=The%20reported%20data%20showed%20that,through%20the%20latest%20follow%2Dup.">completely attack-free</a> following the 16-week primary observation period through the latest follow-up&rdquo; for the treatment of&nbsp;hereditary angioedema.



Moving forward, the company plans to&nbsp;<a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-highlights-its-three-year-strategic">initiate Phase 3 trials of that treatment.</a> It&rsquo;s also still on track to dose the first patient in a Phase 1&nbsp;<a href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-highlights-its-three-year-strategic">study of NTLA-3001,</a> a candidate for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Better, NTLA just announced the first patient was dosed in a Phase 3 trial of NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.



<h2>Verve Therapeutics (VERV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/dna-helix-300x169.png" alt="An image of a DNA helix"><div>Source: Yurchanka Siarhei/Shutterstock</div></div>I also mentioned&nbsp;Verve Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/verv-stock-quote/">VERV</a>) on Feb. 13, as it traded at around $12. After hitting a high of $19, it&rsquo;s now back to $13.38, where it appears to have caught strong support.



At the time, I noted a&nbsp;clinical trial <a href="https://www.vervetx.com/our-programs/verve-101-102">showed that VERVE-101</a>&nbsp;led to reductions of disease-causing LDL-C in people living with HeFH.&nbsp;Even better, further success could expose the company to the&nbsp;<a href="https://www.vervetx.com/our-programs/our-pipeline">31 million people around the world</a>&nbsp;dealing with familial hypercholesterolemia.



Since then,&nbsp;<a href="https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-provides-pipeline-progress-and-reports-0">CEO Sekar Kathiresan, M.D. noted,</a> &ldquo;Looking ahead in 2024, we expect to dose the first patient in the United States, complete enrollment in the ongoing Phase 1b trial of VERVE-101, and provide a data update. We also expect to initiate the Heart-2 Phase 1b trial for VERVE-102 targeting&nbsp;PCSK9&nbsp;in the first half of this year, followed by initiation of a Phase 1b trial for VERVE-201 targeting&nbsp;ANGPTL3&nbsp;in the second half of the year.&rdquo;



Better, the company <a href="https://seekingalpha.com/news/4072171-verve-therapeutics-gaap-eps-of-0_69-beats-0_13-revenue-of-5_14m-beats-3_97m">posted</a> better-than-expected earnings. Fourth quarter EPS of a 69-cent loss beat by 13 cents. It had revenues of $5.14 million &mdash; up nearly 409% year over year &mdash; beat by $3.97 million. It also ended its recent quarter with $624 million in cash.



<h2>Global X Genomics &amp; Biotechnology ETF (GNOM)</h2>



<div><img width="300" height="198" src="https://investorplace.com/wp-content/uploads/2018/11/dnamsn-300x198.jpg" alt=""><div>Source: Shutterstock</div></div>Or, if you want to diversify at a low cost, there&rsquo;s the&nbsp;Global X Genomics &amp; Biotechnology ETF&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gnom-stock-quote/">GNOM</a>), which I also mentioned on Feb. 13.



At the time, it traded at around $11. After testing $12.50, it&rsquo;s now at $11.45, where it appears to have bottomed out. From here, I&rsquo;d initially like to see it retest $12.50. In the long term, I&rsquo;d like to see GNOM test $28 a share again.



<a href="https://www.globalxetfs.com/funds/gnom/">With an expense ratio of 0.50%,</a>&nbsp;the ETF invests in companies that could benefit from gene editing, genomic sequencing, genetic medicine/therapy, computational genomics and biotechnology, as noted by GlobalXETFs.com. What&rsquo;s nice about an ETF like GNOM is I can diversify with its 41 holdings for just $11 a share.



If I were to buy 100 shares, it would cost me $1,100 for that exposure.&nbsp;If I were to buy just one of its 42 holdings &mdash; let&rsquo;s say 100 shares of CRSP &mdash; it would cost me close to $7,300.



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-stocks-that-could-be-the-next-big-thing-in-gene-editing/">3 Stocks That Could Be the Next Big Thing in Gene Editing</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.